---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-26T20:18:27.607596'
end_time: '2025-12-26T20:28:17.728371'
duration_seconds: 590.12
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: EGFR
  gene_symbol: EGFR
  uniprot_accession: P00533
  protein_description: 'RecName: Full=Epidermal growth factor receptor {ECO:0000305};
    EC=2.7.10.1; AltName: Full=Proto-oncogene c-ErbB-1; AltName: Full=Receptor tyrosine-protein
    kinase erbB-1; Flags: Precursor;'
  gene_info: Name=EGFR {ECO:0000312|HGNC:HGNC:3236}; Synonyms=ERBB, ERBB1, HER1;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the protein kinase superfamily. Tyr protein
  protein_domains: Furin-like_Cys-rich_dom. (IPR006211); Furin_repeat. (IPR006212);
    GF_recep_IV. (IPR032778); Growth_fac_rcpt_cys_sf. (IPR009030); Kinase-like_dom_sf.
    (IPR011009)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 27
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P00533
- **Protein Description:** RecName: Full=Epidermal growth factor receptor {ECO:0000305}; EC=2.7.10.1; AltName: Full=Proto-oncogene c-ErbB-1; AltName: Full=Receptor tyrosine-protein kinase erbB-1; Flags: Precursor;
- **Gene Information:** Name=EGFR {ECO:0000312|HGNC:HGNC:3236}; Synonyms=ERBB, ERBB1, HER1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the protein kinase superfamily. Tyr protein
- **Key Domains:** Furin-like_Cys-rich_dom. (IPR006211); Furin_repeat. (IPR006212); GF_recep_IV. (IPR032778); Growth_fac_rcpt_cys_sf. (IPR009030); Kinase-like_dom_sf. (IPR011009)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "EGFR" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'EGFR' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **EGFR** (gene ID: EGFR, UniProt: P00533) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P00533
- **Protein Description:** RecName: Full=Epidermal growth factor receptor {ECO:0000305}; EC=2.7.10.1; AltName: Full=Proto-oncogene c-ErbB-1; AltName: Full=Receptor tyrosine-protein kinase erbB-1; Flags: Precursor;
- **Gene Information:** Name=EGFR {ECO:0000312|HGNC:HGNC:3236}; Synonyms=ERBB, ERBB1, HER1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the protein kinase superfamily. Tyr protein
- **Key Domains:** Furin-like_Cys-rich_dom. (IPR006211); Furin_repeat. (IPR006212); GF_recep_IV. (IPR032778); Growth_fac_rcpt_cys_sf. (IPR009030); Kinase-like_dom_sf. (IPR011009)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "EGFR" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'EGFR' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **EGFR** (gene ID: EGFR, UniProt: P00533) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human EGFR (ERBB1/HER1; UniProt P00533)

Plan status and verification
- Identity verified. The target is human epidermal growth factor receptor, also known as ERBB1/HER1, UniProt P00533, a member of the ERBB receptor tyrosine kinase family with an ectodomain comprising subdomains I–IV (with the domain II dimerization arm), a single transmembrane helix, a juxtamembrane segment, a cytoplasmic tyrosine kinase domain (EC 2.7.10.1), and a C‑terminal tail harboring tyrosine autophosphorylation sites (ERBB family and domain architecture consistent across sources) (kozlova2024celladhesionmolecules pages 4-6, schultz2023egfrtraffickingeffect pages 9-10, comez2024dynamicsofligand pages 41-46).

Key concepts and definitions
- Protein class and enzymatic activity. EGFR is a receptor tyrosine kinase (RTK) that catalyzes ATP‑dependent phosphorylation of tyrosine residues on itself and substrates following activation (EC 2.7.10.1) (tydings2024analysisofegfr pages 22-23, kozlova2024celladhesionmolecules pages 4-6, nadendla2025tyrosinekinasesstructural pages 29-31). 
- Canonical ligands. Multiple EGF‑like ligands bind EGFR, including EGF, TGF‑α, HB‑EGF, betacellulin (BTC), amphiregulin (AREG), epiregulin (EREG), and epigen (EPGN) (kozlova2024celladhesionmolecules pages 4-6, comez2024dynamicsofligand pages 41-46, trenker2024structuraldynamicsof pages 25-26). 
- Activation and dimerization mechanism. In the resting state, intramolecular contacts (including a tether between domains II and IV) keep the dimerization arm concealed; ligand binding to domains I and III rotates/extends the ectodomain, exposes the domain II dimerization arm, and promotes receptor dimerization. Catalytic activation proceeds via formation of an intracellular asymmetric kinase dimer in which the C‑lobe of one kinase allosterically activates the N‑lobe of the other, leading to autophosphorylation on the C‑terminal tail (kozlova2024celladhesionmolecules pages 4-6, schultz2023egfrtraffickingeffect pages 9-10, trenker2024structuraldynamicsof pages 25-26). Ligand‑independent assemblies and oligomers can also form—especially with oncogenic mutations or overexpression—contributing to signaling outside the canonical ligand‑triggered model (schultz2023egfrtraffickingeffect pages 2-3). 
- Downstream pathways. Key signaling axes include RAS–RAF–MEK–ERK (MAPK), PI3K–AKT–mTOR, and JAK–STAT, often engaged via SH2/PTB‑containing adaptors such as GRB2; pathway outputs depend on ligand and dimerization context (tydings2024analysisofegfr pages 22-23, nadendla2025tyrosinekinasesstructural pages 29-31, comez2024dynamicsofligand pages 41-46). 
- Cellular localization and trafficking. EGFR resides at the plasma membrane and continues to signal from early endosomes after internalization. Endocytosis occurs via clathrin‑mediated and clathrin‑independent routes: at lower ligand concentrations, clathrin‑mediated uptake often favors recycling; at high ligand or with increased ubiquitination, receptors are sorted for lysosomal degradation. Nuclear EGFR has been reported in specific contexts and may have transcriptional roles; small molecules can block nuclear translocation in preclinical settings, though clinical utility remains unproven (schultz2023egfrtraffickingeffect pages 9-10, schultz2023egfrtraffickingeffect pages 2-3, kozlova2024celladhesionmolecules pages 4-6).

| Aspect | Key details | Representative recent sources (with year) |
|---|---|---|
| Identity / synonyms / organism | EGFR (ERBB, ERBB1, HER1); human (Homo sapiens); UniProt P00533 | (tydings2024analysisofegfr pages 22-23, comez2024dynamicsofligand pages 41-46, nadendla2025tyrosinekinasesstructural pages 29-31) |
| Protein family and EC | Receptor tyrosine kinase (ErbB family); EC 2.7.10.1 (tyrosine-protein kinase) | (tydings2024analysisofegfr pages 22-23, nadendla2025tyrosinekinasesstructural pages 29-31, kozlova2024celladhesionmolecules pages 4-6) |
| Domain architecture (ECD I–IV, TM, JM, KD, tail) & dimerization arm | ECD domains I–IV (cys-rich II & IV) with domain-II dimerization arm; single-pass TM helix; juxtamembrane (JM) region; intracellular kinase domain (KD) and C-terminal tail with phosphorylation sites | (kozlova2024celladhesionmolecules pages 4-6, schultz2023egfrtraffickingeffect pages 9-10, comez2024dynamicsofligand pages 41-46) |
| Canonical ligands | EGF; TGF-α; HB-EGF; betacellulin (BTC); amphiregulin (AREG); epiregulin (EREG); epigen (EPGN) | (kozlova2024celladhesionmolecules pages 4-6, comez2024dynamicsofligand pages 41-46, trenker2024structuraldynamicsof pages 25-26) |
| Activation mechanism | Ligand binding → ECD rotation/exposure of dimer arm → ECD dimerization; asymmetric kinase-domain (allosteric) dimer activates catalytic site; ligand-independent/mutant-driven oligomers also occur | (tydings2024analysisofegfr pages 22-23, schultz2023egfrtraffickingeffect pages 9-10, trenker2024structuraldynamicsof pages 25-26) |
| Major downstream pathways | RAS–RAF–MAPK (ERK); PI3K–AKT–mTOR; JAK–STAT and adaptor-mediated cascades (e.g., GRB2) | (tydings2024analysisofegfr pages 22-23, nadendla2025tyrosinekinasesstructural pages 29-31, comez2024dynamicsofligand pages 41-46) |
| Cellular localization | Primarily plasma membrane; signaling continues from early endosomes; trafficked to lysosomes for degradation; nuclear translocation reported in specific contexts | (schultz2023egfrtraffickingeffect pages 9-10, kozlova2024celladhesionmolecules pages 4-6, comez2024dynamicsofligand pages 41-46) |
| Endocytosis / trafficking routes | Clathrin-mediated endocytosis (low ligand → recycling); clathrin-independent/ubiquitin-dependent uptake (high ligand → lysosomal degradation); trafficking modulates signal duration and resistance | (schultz2023egfrtraffickingeffect pages 9-10, schultz2023egfrtraffickingeffect pages 2-3) |
| Nuclear EGFR mention | Nuclear EGFR (nEGFR) documented; linked to transcriptional roles and clinical implications; inhibitors of nuclear translocation are experimental | (schultz2023egfrtraffickingeffect pages 2-3, schultz2023egfrtraffickingeffect pages 9-10) |
| Heterodimerization within ERBB family | Forms heterodimers with HER2/ERBB2, HER3/ERBB3, HER4/ERBB4; heterodimers (e.g., EGFR/HER2) alter signaling strength, membrane dynamics, and endocytosis | (tydings2024analysisofegfr pages 22-23, trenker2024structuraldynamicsof pages 25-26) |


*Table: Concise reference table summarizing human EGFR identity, domains, ligands, activation, key pathways, localization, and trafficking with representative 2023–2024 sources for quick verification.*

Recent structural and mechanistic developments (2023–2024)
- EGFR inhibitory biologics and binding hotspots. A 2024 analysis integrates structural interfaces of EGFR ligands and inhibitory biologics, highlighting the ectodomain binding surfaces and their relationship to activation and resistance; it synthesizes earlier crystallography and nanobody/antibody complexes to guide rational biologic design (Protein Science, 2024; https://doi.org/10.1002/pro.5141) (tydings2024analysisofegfr pages 22-23). 
- ERBB family structural dynamics and glycosylation. Recent cryo‑EM work in the ERBB family (HER4 and HER2/HER4) emphasizes that ligand identity and glycosylation tune dimer dynamics and stability, and underscores the loose linkage between ligand binding and kinase activation previously observed for EGFR; these principles generalize to EGFR and heterodimers (eLife, 2024; https://doi.org/10.7554/elife.92873) (trenker2024structuraldynamicsof pages 25-26). 
- Trafficking–activation coupling. Contemporary reviews detail how dimerization state, mutation, and endocytic routing (clathrin‑dependent vs independent) modulate signaling duration and TKI responses, and note preclinical strategies that combine TKIs with trafficking modulators (Frontiers in Oncology, 2023; https://doi.org/10.3389/fonc.2023.1258371) (schultz2023egfrtraffickingeffect pages 9-10, schultz2023egfrtraffickingeffect pages 2-3). 
- Mechanistic summary of ectodomain–kinase linkage. Updated reviews summarize how ligand binding exposes the dimerization arm and how asymmetric kinase dimers effect catalysis, consolidating structural and biophysical evidence across the last two decades into current models (Cells, 2024; https://doi.org/10.3390/cells13221919) (kozlova2024celladhesionmolecules pages 4-6).

Current applications and real‑world implementations in oncology (with 2023–2024 data)
- First‑line EGFR‑mutated NSCLC: amivantamab+lazertinib vs osimertinib (MARIPOSA). In the phase 3 MARIPOSA trial (NEJM, 2024; published October 24, 2024), amivantamab plus lazertinib significantly prolonged median PFS versus osimertinib (23.7 vs 16.6 months; HR 0.70, 95% CI 0.58–0.85), with similar ORR (86% vs 85%) and longer median duration of response (25.8 vs 16.8 months); interim OS HR 0.80 (95% CI 0.61–1.05) (https://www.nejm.org/doi/full/10.1056/NEJMoa2403614) (cho2024amivantamabpluslazertinib pages 1-4). 
- First‑line EGFR‑mutated NSCLC: osimertinib+chemotherapy (FLAURA‑2). Contemporary reviews summarizing FLAURA‑2 report that adding platinum–pemetrexed to first‑line osimertinib significantly improved PFS versus osimertinib alone (e.g., 29.4 vs 19.9 months; HR ~0.62), with increased grade ≥3 toxicities; this regimen received U.S. FDA approval in February 2024 (Lung Cancer: Targets and Therapy, 2024; https://doi.org/10.2147/LCTT.S467169) (arter2024spotlightonpatritumab pages 2-4). 
- Post‑TKI sequencing and HER3‑DXd. Expert commentary in 2024 positions patritumab deruxtecan (HER3‑DXd) as active after osimertinib, with median PFS ~5.5 months in a heavily pretreated cohort (HERTHENA‑Lung01), supporting its role in later‑line sequencing while first‑line combination strategies (osimertinib+chemo or amivantamab+lazertinib) aim to extend the pre‑resistance interval (https://doi.org/10.2147/LCTT.S467169) (arter2024spotlightonpatritumab pages 4-5, arter2024spotlightonpatritumab pages 2-4). 
- Clinical context of ctDNA and prognostic stratification. A narrative review highlights that in FLAURA‑2, baseline detectable plasma EGFR mutations (ctDNA) were prognostic and associated with greater benefits from osimertinib+chemotherapy, while on‑treatment EGFRmut clearance was prognostic but not specifically predictive of differential benefit; similar ctDNA‑based PFS analyses were reported in MARIPOSA exploratory work, supporting clinical integration of ctDNA for risk stratification (Current Oncology, 2025; https://doi.org/10.3390/curroncol32080448) (roy2025recentadvancesin pages 25-29).

Expert opinions and guidance (authoritative perspectives)
- Practice‑shaping trials. NEJM MARIPOSA defines amivantamab+lazertinib as a first‑line option with superior PFS to osimertinib monotherapy in EGFR Ex19del/L858R NSCLC (NEJM, 2024; https://www.nejm.org/doi/full/10.1056/NEJMoa2403614) (cho2024amivantamabpluslazertinib pages 1-4). 
- Combinations vs monotherapy. Contemporary expert overviews emphasize that first‑line combination strategies (osimertinib+chemotherapy, amivantamab+lazertinib) prolong pre‑resistance duration relative to osimertinib alone but carry higher treatment‑related toxicity, necessitating individualized risk–benefit assessment (https://doi.org/10.2147/LCTT.S467169) (arter2024spotlightonpatritumab pages 2-4, arter2024spotlightonpatritumab pages 4-5). 
- ctDNA in management. Recent analyses underscore the utility of ctDNA for prognostication and treatment monitoring in EGFR‑mutated NSCLC clinical trials, aligning with the trend toward guideline‑endorsed liquid biopsy as a complement to tissue testing (https://doi.org/10.3390/curroncol32080448) (roy2025recentadvancesin pages 25-29). 

Relevant statistics and epidemiology
- Mutation prevalence and spectrum. In advanced non‑squamous NSCLC, activating EGFR mutations occur in approximately 15–50% of cases globally, with exon 19 deletions and L858R substitutions accounting for ~85–90% of EGFR‑mutant tumors; MARIPOSA enrolled Ex19del/L858R and stratified by ancestry, reflecting higher prevalence in East Asian populations (NEJM, 2024; https://www.nejm.org/doi/full/10.1056/NEJMoa2403614) (cho2024amivantamabpluslazertinib pages 1-4). Reviews also emphasize geographic variation in EGFR mutation frequency, with higher rates in East Asia than in Western cohorts, influencing trial demographics and practice patterns (Lung Cancer: Targets and Therapy, 2024; https://doi.org/10.2147/LCTT.S467169) (arter2024spotlightonpatritumab pages 2-4).

Focused functional annotation of EGFR (mechanism and site of action)
- Molecular function. EGFR’s primary biochemical function is receptor‑mediated tyrosine phosphorylation of its own C‑terminal tail and of recruited substrates following ligand binding and dimerization, initiating downstream signaling cascades controlling proliferation, survival, and differentiation (tydings2024analysisofegfr pages 22-23, kozlova2024celladhesionmolecules pages 4-6). 
- Substrate specificity. Substrate recognition is largely indirect, via recruitment of SH2/PTB‑containing adaptors (e.g., GRB2) to phosphotyrosine motifs on EGFR, which in turn engage downstream effectors (RAS–RAF–MEK–ERK; PI3K–AKT–mTOR; JAK–STAT) (tydings2024analysisofegfr pages 22-23, nadendla2025tyrosinekinasesstructural pages 29-31, comez2024dynamicsofligand pages 41-46). 
- Cellular compartment and dynamics. EGFR functions primarily at the plasma membrane and in early endosomes; clathrin‑mediated endocytosis usually favors recycling and sustained signaling, whereas clathrin‑independent uptake coupled to ubiquitination promotes lysosomal degradation. Nuclear translocation has been described in some contexts and is under investigation pharmacologically (schultz2023egfrtraffickingeffect pages 9-10, schultz2023egfrtraffickingeffect pages 2-3, kozlova2024celladhesionmolecules pages 4-6).

Expert analysis and synthesis
- Alignment with domain/family expectations. The domain architecture, activation modality via asymmetric kinase dimer, and integration into canonical RTK pathways collectively confirm that human EGFR (ERBB1/HER1) matches UniProt P00533 descriptions and ERBB family paradigms, fulfilling the ambiguity checks required before analysis (kozlova2024celladhesionmolecules pages 4-6, schultz2023egfrtraffickingeffect pages 9-10, comez2024dynamicsofligand pages 41-46). 
- Translational trajectory (2023–2024). Two pivotal strategies advanced first‑line care: (1) vertical intensification with osimertinib+platinum–pemetrexed (FLAURA‑2) and (2) receptor‑level dual targeting (amivantamab EGFR–MET bispecific) plus a brain‑penetrant TKI (lazertinib) in MARIPOSA. Both improve PFS over osimertinib alone but present distinct safety profiles; patient selection may be influenced by baseline disease burden, comorbidities, and ctDNA‑based risk stratification patterns observed in exploratory analyses (cho2024amivantamabpluslazertinib pages 1-4, arter2024spotlightonpatritumab pages 2-4, roy2025recentadvancesin pages 25-29). 
- Open questions. Optimizing sequencing after first‑line combination therapy, integrating HER3‑directed ADCs, and exploiting trafficking‑dependent vulnerabilities remain active areas; mechanistic insights into ligand‑independent oligomerization and heterodimer dynamics (with HER2/HER3/HER4) continue to inform next‑generation inhibitor and biologic design (schultz2023egfrtraffickingeffect pages 9-10, trenker2024structuraldynamicsof pages 25-26, tydings2024analysisofegfr pages 22-23).

URLs and publication dates (selected)
- NEJM MARIPOSA: Amivantamab+lazertinib vs osimertinib first‑line; published October 24, 2024; https://www.nejm.org/doi/full/10.1056/NEJMoa2403614 (cho2024amivantamabpluslazertinib pages 1-4). 
- FLAURA‑2 overview and FDA approval context: Lung Cancer: Targets and Therapy; July 2024; https://doi.org/10.2147/LCTT.S467169 (arter2024spotlightonpatritumab pages 2-4, arter2024spotlightonpatritumab pages 4-5). 
- EGFR inhibitory biologics interfaces: Protein Science; September 2024; https://doi.org/10.1002/pro.5141 (tydings2024analysisofegfr pages 22-23). 
- ERBB structural dynamics and glycosylation (HER4/HER2): eLife; March 2024; https://doi.org/10.7554/eLife.92873 (trenker2024structuraldynamicsof pages 25-26). 
- EGFR trafficking and dimerization/mutation review: Frontiers in Oncology; September 2023; https://doi.org/10.3389/fonc.2023.1258371 (schultz2023egfrtraffickingeffect pages 9-10, schultz2023egfrtraffickingeffect pages 2-3). 
- Cell adhesion molecules modulating EGFR: Cells; November 2024; https://doi.org/10.3390/cells13221919 (kozlova2024celladhesionmolecules pages 4-6). 
- ctDNA prognostic utility in trial contexts: Current Oncology; August 2025; https://doi.org/10.3390/curroncol32080448 (roy2025recentadvancesin pages 25-29).

Limitations and scope note
- Where explicit guideline text (e.g., NCCN/ESMO/ASCO) and some real‑world datasets were not directly accessible in the current context, we cited high‑quality trial reports and recent peer‑reviewed syntheses capturing the 2023–2024 practice changes and ctDNA‑related findings. All claims are restricted to the evidence listed above.


References

1. (kozlova2024celladhesionmolecules pages 4-6): Irina Kozlova and Vladimir Sytnyk. Cell adhesion molecules as modulators of the epidermal growth factor receptor. Cells, 13:1919, Nov 2024. URL: https://doi.org/10.3390/cells13221919, doi:10.3390/cells13221919. This article has 11 citations and is from a poor quality or predatory journal.

2. (schultz2023egfrtraffickingeffect pages 9-10): Destiny F. Schultz, Daniel D. Billadeau, and Seetharama D. Jois. Egfr trafficking: effect of dimerization, dynamics, and mutation. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1258371, doi:10.3389/fonc.2023.1258371. This article has 25 citations and is from a poor quality or predatory journal.

3. (comez2024dynamicsofligand pages 41-46): D Comez. Dynamics of ligand and nanobody binding at cxcr4/egfr complexes. Unknown journal, 2024.

4. (tydings2024analysisofegfr pages 22-23): Claiborne W. Tydings, Bhuminder Singh, Adam W. Smith, Kaitlyn V. Ledwitch, Benjamin P. Brown, Christine M. Lovly, Allison S. Walker, and Jens Meiler. Analysis of egfr binding hotspots for design of new egfr inhibitory biologics. Protein Science : A Publication of the Protein Society, Sep 2024. URL: https://doi.org/10.1002/pro.5141, doi:10.1002/pro.5141. This article has 6 citations.

5. (nadendla2025tyrosinekinasesstructural pages 29-31): Eswar Kumar Nadendla, Gangadhar P Vadla, Manohar Radhakrishnan, and Raghavendra Sashi Krishna Nagampalli. Tyrosine kinases: structural insights and mechanistic roles in cancer progression and therapeutics. May 2025. URL: https://doi.org/10.20944/preprints202505.0180.v1, doi:10.20944/preprints202505.0180.v1.

6. (trenker2024structuraldynamicsof pages 25-26): Raphael Trenker, Devan Diwanji, Tanner Bingham, Kliment A Verba, and Natalia Jura. Structural dynamics of the active her4 and her2/her4 complexes is finely tuned by different growth factors and glycosylation. eLife, Mar 2024. URL: https://doi.org/10.7554/elife.92873, doi:10.7554/elife.92873. This article has 17 citations and is from a domain leading peer-reviewed journal.

7. (schultz2023egfrtraffickingeffect pages 2-3): Destiny F. Schultz, Daniel D. Billadeau, and Seetharama D. Jois. Egfr trafficking: effect of dimerization, dynamics, and mutation. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1258371, doi:10.3389/fonc.2023.1258371. This article has 25 citations and is from a poor quality or predatory journal.

8. (cho2024amivantamabpluslazertinib pages 1-4): Byoung C. Cho, Shun Lu, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jong-Seok Lee, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee-Chen Chang, Hiroshige Yoshioka, James C.-H. Yang, Michael Thomas, Danny Nguyen, Sai-Hong I. Ou, Sanjay Mukhedkar, Kumar Prabhash, Manolo D’Arcangelo, Jorge Alatorre-Alexander, Juan C. Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet A.N. Şendur, Ozan Yazici, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Antonio Passaro, Sang-We Kim, Shirish M. Gadgeel, John Xie, Tao Sun, Melissa Martinez, Mariah Ennis, Elizabeth Fennema, Mahesh Daksh, Dawn Millington, Isabelle Leconte, Ryota Iwasawa, Patricia Lorenzini, Mahadi Baig, Sujay Shah, Joshua M. Bauml, S. Martin Shreeve, Seema Sethi, Roland E. Knoblauch, and Hidetoshi Hayashi. Amivantamab plus lazertinib in previously untreated <i>egfr</i> -mutated advanced nsclc. New England Journal of Medicine, 391:1486-1498, Oct 2024. URL: https://doi.org/10.1056/nejmoa2403614, doi:10.1056/nejmoa2403614. This article has 343 citations and is from a highest quality peer-reviewed journal.

9. (arter2024spotlightonpatritumab pages 2-4): Zhaohui Arter and Misako Nagasaka. Spotlight on patritumab deruxtecan (her3-dxd) from herthena lung01. is a median pfs of 5.5 months enough in light of flaura-2 and mariposa? Lung Cancer: Targets and Therapy, 15:115-121, Jul 2024. URL: https://doi.org/10.2147/lctt.s467169, doi:10.2147/lctt.s467169. This article has 4 citations.

10. (arter2024spotlightonpatritumab pages 4-5): Zhaohui Arter and Misako Nagasaka. Spotlight on patritumab deruxtecan (her3-dxd) from herthena lung01. is a median pfs of 5.5 months enough in light of flaura-2 and mariposa? Lung Cancer: Targets and Therapy, 15:115-121, Jul 2024. URL: https://doi.org/10.2147/lctt.s467169, doi:10.2147/lctt.s467169. This article has 4 citations.

11. (roy2025recentadvancesin pages 25-29): Prabhat Gautam Roy, Davida Reingold, Neha Pathak, Saurav Verma, Aarushi Gupta, N. Meti, C. Moltó, P. Malik, Geordie Linford, and A. Mittal. Recent advances in the management of egfr-mutated advanced non-small cell lung cancer—a narrative review. Current Oncology, Aug 2025. URL: https://doi.org/10.3390/curroncol32080448, doi:10.3390/curroncol32080448. This article has 4 citations and is from a poor quality or predatory journal.

## Citations

1. schultz2023egfrtraffickingeffect pages 2-3
2. tydings2024analysisofegfr pages 22-23
3. trenker2024structuraldynamicsof pages 25-26
4. kozlova2024celladhesionmolecules pages 4-6
5. cho2024amivantamabpluslazertinib pages 1-4
6. arter2024spotlightonpatritumab pages 2-4
7. roy2025recentadvancesin pages 25-29
8. schultz2023egfrtraffickingeffect pages 9-10
9. comez2024dynamicsofligand pages 41-46
10. nadendla2025tyrosinekinasesstructural pages 29-31
11. arter2024spotlightonpatritumab pages 4-5
12. https://doi.org/10.1002/pro.5141
13. https://doi.org/10.7554/elife.92873
14. https://doi.org/10.3389/fonc.2023.1258371
15. https://doi.org/10.3390/cells13221919
16. https://www.nejm.org/doi/full/10.1056/NEJMoa2403614
17. https://doi.org/10.2147/LCTT.S467169
18. https://doi.org/10.3390/curroncol32080448
19. https://doi.org/10.7554/eLife.92873
20. https://doi.org/10.3390/cells13221919,
21. https://doi.org/10.3389/fonc.2023.1258371,
22. https://doi.org/10.1002/pro.5141,
23. https://doi.org/10.20944/preprints202505.0180.v1,
24. https://doi.org/10.7554/elife.92873,
25. https://doi.org/10.1056/nejmoa2403614,
26. https://doi.org/10.2147/lctt.s467169,
27. https://doi.org/10.3390/curroncol32080448,